DIAGNOS Positioned for Growth as CARA Advances Toward Major Regulatory Approvals
DIAGNOS Inc. (TSXV: ADK) is a medical AI company that develops and commercializes CARA (Computer Assisted Retinal Analysis), a cloud-based, AI-powered software platform for the early detection of retinal diseases and systemic conditions. CARA integrates with standard fundus cameras via a secure internet connection to deliver real-time pathology detection using proprietary deep-learning algorithms. The current version of CARA can detect early signs of age-related macular degeneration (AMD) and diabetic retinopathy. The platform is used by optometrists, optical chains, and medical institutions, and has cumulatively assessed 400,000 patients across 140 clinics in 16 countries.
